Connect with others who understand.

Sign up Log in
Resources
About myRAteam
Powered By
SPONSORED BY

Why Some People With RA Stop Taking TNF Inhibitors and Change Treatments [FAQ VIDEO]

Posted on June 20, 2025


It’s common for people with rheumatoid arthritis (RA) to take tumor necrosis factor (TNF) inhibitors.1 In fact, about 90 percent of people diagnosed with RA start treatment with a TNF inhibitor as their first biologic.2 However, some people may not benefit from or tolerate these treatments. Additionally, they could work for a while and eventually become less effective.1 For these reasons, about 30 percent to 40 percent of people with RA stop taking TNF inhibitors.3

Dr. Siddharth Tambar spoke with myRAteam to explain why some people with RA might stop taking TNF inhibitors and change treatments. Dr. Tambar is a rheumatologist who earned his medical degree from the State University of New York at Syracuse and completed his internal medicine and rheumatology training at Northwestern Memorial Hospital in Chicago. He’s the owner of the Chicago Arthritis and Regenerative Medicine clinic.

Why Some People With RA Stop Taking TNF Inhibitors and Change Treatments

Transcript

00:00:00:00 - 00:00:27:11
Dr. Siddharth Tambar
The ultimate goal of treating rheumatoid arthritis is to reach remission or low disease activity. If a treatment isn't getting you there after about 3 to 6 months, or if it has stopped working effectively, it may be time to try something else. Hi, I'm Dr. Siddharth Tambar, and today we'll discuss why some people with RA might stop taking TNF inhibitors and change treatments.

00:00:27:13 - 00:01:03:06
Dr. Siddharth Tambar
TNF inhibitors are biologic medications that block a protein called tumor necrosis factor, which causes inflammation in people with RA. These biologics have been around since the 1990s and were a breakthrough treatment for treating RA. TNF inhibitors are the most common biologic in RA treatment to use first, but like all medications, they may not be right for everyone. For example, if you've been using a TNF inhibitor and haven't achieved low disease activity or remission after 3 to 6 months, the guidelines suggest altering your treatment regimen.

00:01:03:11 - 00:01:32:05
Dr. Siddharth Tambar
We call this ‘treat to target.’ In this case, our target is low disease activity or remission. If you're not hitting that target, it may be time to adjust your treatment plan. This could mean changing the dosage, adding additional medication, or switching to a medication with a different mechanism of action, meaning it works in a different way. Sometimes people who have been on a TNF inhibitor for a while and experience improvement initially might notice their symptoms returning.

00:01:32:07 - 00:02:06:19
Dr. Siddharth Tambar
This could mean the medication is no longer working effectively. You might experience flares with pain, swelling, tenderness or warmth in previously affected joints. In such cases, switching to a treatment with a different mechanism of action, or trying another TNF inhibitor might be beneficial. RA can cause chronic inflammation that, if left unchecked, might damage joints and surrounding tissues, leading to joint issues and an increased risk of other health problems such as heart disease and infections.

00:02:06:21 - 00:02:38:15
Dr. Siddharth Tambar
Our goal is to prevent RA from progressing this way. Thankfully, there are many more treatment options today than there were just a decade ago. So if your RA medication isn't working, there are other paths to help you achieve remission. Regular check ins with your rheumatologist and open conversations where you share details, symptoms, and personal goals are key. You and your provider can work together to create a plan that reflects how you're doing now, and what goals you want to achieve in the future.

00:02:38:17 - 00:02:45:18
Dr. Siddharth Tambar
Learn more and connect in myRAteam.com.


“TNF inhibitors are biologic medications that block a protein called tumor necrosis factor, which causes inflammation in people with RA,” Dr. Tambar said. The aim of RA treatment is to reach remission or low disease activity.2 If a specific RA treatment doesn’t help you achieve that goal in about three to six months or it stops working effectively, it may be time to try something else.2,4,5

In remission, rheumatoid arthritis is either minimally active or inactive.3,6 This means you may experience few or no RA symptoms, such as joint pain, swelling, or stiffness.7 However, remission doesn’t mean your RA disappears completely.6 Instead, it means you have a lower risk of joint damage, fewer symptoms, and very low or no signs of RA in your lab tests.7 Treating your RA and getting to remission may also decrease your risk of RA comorbidities (coexisting conditions) like osteoporosis, heart disease, and serious infections.8,9

Your doctor will monitor your RA regularly to see whether your TNF inhibitor is working.6 Below are several reasons it might be time to change your TNF inhibitor treatment.

No Improvement in Disease Activity After 3 to 6 Months

“If you’ve been using a TNF inhibitor and haven’t achieved low disease activity or remission after three to six months, the guidelines suggest altering your treatment regimen,” Dr. Tambar said.3,4,5 “We call this treat to target. In this case, our target is low disease activity or remission. If you’re not hitting that target, it may be time to adjust your treatment plan.”3,5

Less Relief Over Time With a TNF Inhibitor

In some cases, you may initially find symptom relief with a TNF inhibitor, but the drug later stops controlling your symptoms.2 “This could mean the medication is no longer working effectively,” Dr. Tambar said. “You might experience flares with pain, swelling, tenderness, or warmth in previously affected joints.”

Adverse Events

Some people experience adverse events when taking medications. The U.S. Food and Drug Administration (FDA) defines adverse events as “unfavorable or unintended” health effects linked to a medication, therapy, or procedure.10

One study found that experiencing adverse events is the third most common reason for stopping a TNF inhibitor.1

Insurance or Cost Issues

Sometimes people stop taking TNF inhibitors and change medications because of issues with health insurance or the cost of medication.1 You and your doctor should work together and consider these factors when determining your RA treatment plan.3

The American College of Rheumatology (ACR) developed guidelines to help doctors select RA treatments. These guidelines support switching to a drug from a different class if a TNF inhibitor doesn’t work for you.5 Although some individuals may respond to a second TNF inhibitor, several studies show that switching to a drug in a different class may lead to improved clinical outcomes.1,2,11,12 For these reasons, your doctor may suggest a drug from a different class rather than another TNF inhibitor.

“Thankfully, there are many more treatment options today than there were just a decade ago, so if your RA medication isn’t working, there are other paths to help you achieve remission,” Dr. Tambar said.

In closing, Dr. Tambar emphasized the importance of monitoring: “Regular check-ins with your rheumatologist and open conversations where you share detailed symptoms and personal goals are key.”

Everyone living with RA should be monitored frequently by their doctor to ensure that their treatment is working.4-6 During these checkups, your doctor will ask about your symptoms and how you’re feeling.4,5 They’ll also perform an exam, blood tests, and imaging studies to evaluate joint health.7 Based on the results of those evaluations, they’ll share possible treatment recommendations with you.

Talk with your doctor about RA treatment changes and whether switching drugs may help your symptoms. “You and your provider can work together to create a plan that reflects how you’re doing now and what goals you want to reach in the future,” Dr. Tambar said.


AbbVie ABBV-US-01983-MC Approved 6/2025

References
  1. Wei W, Knapp K, Wang L, et al. Treatment persistence and clinical outcomes of tumor necrosis factor inhibitor cycling or switching to a new mechanism of action therapy: real-world observational study of rheumatoid arthritis patients in the United States with prior tumor necrosis factor inhibitor therapy. Adv Ther. 2017;34(8):1936-1952. doi:10.1007/s12325-017-0578-8
  2. Johnson KJ, Sanchez HN, Schoenbrunner N. Defining response to TNF-inhibitors in rheumatoid arthritis: the negative impact of anti-TNF cycling and the need for a personalized medicine approach to identify primary non-responders. Clin Rheumatol. 2019;38(11):2967-2976. doi:10.1007/s10067-019-04684-1
  3. Taylor PC, Matucci Cerinic M, Alten R, Avouac J, Westhovens R. Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes. Ther Adv Musculoskelet Dis. 2022;14:1759720X221114101. doi:10.1177/1759720X221114101
  4. Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3-18. doi:10.1136/ard-2022-223356
  5. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73(7):924-939. doi:10.1002/acr.24596
  6. Ajeganova S, Huizinga T. Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations. Ther Adv Musculoskelet Dis. 2017;9(10):249-262. doi:10.1177/1759720X17720366
  7. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023-2038. doi:10.1016/S0140-6736(16)30173-8
  8. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205-2219. doi:10.1056/NEJMra1004965
  9. Mehta B, Pedro S, Ozen G, et al. Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study. RMD Open. 2019;5(1):e000935. doi:10.1136/rmdopen-2019-000935
  10. Adverse event. National Center for Advancing Translational Sciences. Accessed April 21, 2025. https://toolkit.ncats.nih.gov/glossary/adverse-event/
  11. Migliore A, Pompilio G, Integlia D, Zhuo J, Alemao E. Cycling of tumor necrosis factor inhibitors versus switching to different mechanism of action therapy in rheumatoid arthritis patients with inadequate response to tumor necrosis factor inhibitors: a Bayesian network meta-analysis. Ther Adv Musculoskelet Dis. 2021;13:1759720X211002682. doi:10.1177/1759720X211002682
  12. Gottenberg JE, Brocq O, Perdriger A, et al. Non-TNF-targeted biologic vs a second anti-tnf drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: a randomized clinical trial. JAMA. 2016;316(11):1172-1180. doi:10.1001/jama.2016.13512
Siddharth Tambar, M.D. is a rheumatologist in Chicago, Illinois. He is the owner of the clinic Chicago Arthritis and Regenerative Medicine. Learn more about him here.
Torrey Kim, a writer for MyHealthTeam, in collaboration with AbbVie is a freelance writer with MyHealthTeam. Learn more about her here.
All updates must be accompanied by text or a picture.

We'd love to hear from you! Please share your name and email to post and read comments.

You'll also get the latest articles directly to your inbox.

Subscriber Photo Subscriber Photo Subscriber Photo
238,750 members
Subscribe
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service.
Privacy Policy Terms of Use
All updates must be accompanied by text or a picture.

Subscribe now to ask your question, get answers, and stay up to date on the latest articles.

Get updates directly to your inbox.

Subscriber Photo Subscriber Photo Subscriber Photo
238,750 members
Subscribe
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service.
Privacy Policy Terms of Use

Thank you for subscribing!

Become a member to get even more